Search stocks, ETFs, IPOs & more
Welcome to Multibagg AI
Log in to access personalized features
Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Latest stock market news, company updates, and price movements. Stay updated with market trends, earnings insights, and investment analysis.
The Indian government's plan to sell a 60.72% stake in IDBI Bank has been cancelled after bids failed to meet the reserve price, raising key valuation concerns.
Iran's primary nuclear enrichment facility at Natanz was hit by a US-Israeli airstrike, escalating regional tensions and impacting global oil prices despite reports of no radiation leaks.
The Indian IT sector faces a severe downturn in 2026, with the Nifty IT index plummeting due to AI disruption fears, creating a debate on whether stocks are undervalued.
Dr. Reddy's Laboratories has launched Obeda, India's first DCGI-approved generic semaglutide injection for Type 2 diabetes, priced at INR 4,200 per month.
Escalating conflict in West Asia involving Iran and Israel has triggered a sharp sell-off in Indian stock markets, wiping out investor wealth amid surging oil prices.
Iran launched two intermediate-range ballistic missiles at the strategic US-UK military base on Diego Garcia, signaling a major escalation in the ongoing conflict.
As the US-Iran war enters its third week, President Trump confronts surging global energy prices, diplomatic isolation from key allies, and an unclear exit strategy.
Economists warn a prolonged West Asia conflict could push crude oil above $100 per barrel, potentially driving India's retail inflation above 5% and slowing economic growth.
Dr. Reddy's Laboratories has launched Obeda, the first DCGI-approved generic semaglutide injection in India, for the management of Type 2 diabetes at a competitive price.
Russian President Vladimir Putin declares unwavering support for Iran as its conflict with the US and Israel escalates, deepening a global energy crisis and raising fears of a wider war.
Indian and other Asian refiners are exploring resuming crude oil purchases from Iran following a temporary 30-day US sanctions waiver aimed at easing global energy shortages.
Novo Nordisk's patent on the blockbuster drug semaglutide expires in India, paving the way for numerous generic versions and a potential 70% price reduction.
HDFC Bank has terminated three senior executives following an internal investigation into the alleged mis-selling of high-risk Credit Suisse AT1 bonds to retail customers.
Dr. Reddy's Laboratories has launched Obeda, the first DCGI-approved generic semaglutide injection in India for type 2 diabetes, following the drug's patent expiry.
With Novo Nordisk's semaglutide patent expiring in March 2026, Indian pharmaceutical leaders like Dr. Reddy's and Sun Pharma are launching generic versions, reshaping diabetes and obesity treatment.
Zydus Lifesciences is set to launch its generic Semaglutide injection in India upon patent expiry, featuring a novel reusable pen to improve affordability for diabetes and obesity treatment.
